The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
NCT01319383
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
Vorinostat
Sponsor
University of North Carolina, Chapel Hill
Collaborators
[object Object]
[object Object]
[object Object]